ARUP Institute for Clinical and Experimental Pathology
Konnick, Eric Q.; Williams, Sheri M.; Ashwood, Edward R.; Hillyard, David R.;
Performance Characteristics of the COBAS HCV TaqMan ASR Using Armored RNA Calibrators
As improved therapies have become available for Hepatititis C Virus (HCV) infection, the use of assays to quantitate HCV RNA has increased dramatically (3, 14, 16). The initial use of these assays was to predict the likelihood of therapy based on baseline HCV RNA levels. These reports indicated that HCV RNA levels >2,000,000 HCV RNA copies/mL were indicative of a decreased response to therapy. Other studies have suggested that the presence or absence of HCV RNA at a particular time point during therapy is predictive of relapse (5, 18). Recent data, including that from pegylated interferon treatment studies (2, 4, 6, 7, 17), have provided additional incentive for HCV RNA quantitative monitoring. This work suggests that quantitative HCV testing can be used to identify patients for whom HCV viral load does not decrease greater than 2 logs during the first 12 weeks of treatment. Such patients are found to have a high likelihood of treatment failure(1, 4, 12, 19).